Adolescents with atopic dermatitis experience a higher prevalence and a higher frequency of bullying compared with their peers who do not have atopic dermatitis, according to the results of a new ...

Adolescents with AD have reported appearance-based bullying. To evaluate the association between AD and the prevalence and frequency of bullying, researchers analyzed cross-sectional data from adult ...

Findings seen through 76 weeks of treatment for adolescents taking 15- or 30mg doses for moderate to severe atopic dermatitis. HealthDay News — Long-term treatment of adolescents with moderate to ...

Please provide your email address to receive an email when new articles are posted on . By week 76, over 82% of patients treated with 15 mg or 30 mg of upadacitinib reached EASI 75. Upadacitinib ...

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 ECZTRA 6 trial evaluated tralokinumab in ...

Upadacitinib was found to be effective over the long-term in adolescents with moderate-to-severe atopic dermatitis (AD). Investigators analyzed data from three phase 3 randomized clinical trials ...

A new study published in the journal of Pediatric Dermatology revealed that treatment with dupilumab achieved effective ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) ...

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA ...